These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29739505)

  • 1. Semaglutide, Ertugliflozin, and Deflazacort.
    Hussar DA; Bailey KJ
    J Am Pharm Assoc (2003); 2018; 58(3):321-325. PubMed ID: 29739505
    [No Abstract]   [Full Text] [Related]  

  • 2. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ertugliflozin: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):513-519. PubMed ID: 29476348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
    Hu J; Deng A; Zhao Y
    Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.
    Cherney DZI; McGuire DK; Charbonnel B; Cosentino F; Pratley R; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu CC; Cannon CP;
    Circulation; 2021 Feb; 143(6):602-605. PubMed ID: 33186063
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
    Heymsfield SB; Raji A; Gallo S; Liu J; Pong A; Hannachi H; Terra SG
    Obesity (Silver Spring); 2020 Apr; 28(4):724-732. PubMed ID: 32202075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ertugliflozin, renoprotection and potential confounding by muscle wasting.
    Groothof D; Post A; Gans ROB; Bakker SJL
    Diabetologia; 2022 May; 65(5):906-907. PubMed ID: 34940888
    [No Abstract]   [Full Text] [Related]  

  • 8. Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
    Cherney DZI; Charbonnel B; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Shih WJ; Frederich R; Maldonado M; Pong A; Cannon CP;
    Diabetologia; 2022 May; 65(5):908-911. PubMed ID: 35238955
    [No Abstract]   [Full Text] [Related]  

  • 9. Deflazacort--an alternative to prednisolone?
    Drug Ther Bull; 1999 Aug; 37(8):57-8. PubMed ID: 10696685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Drugs 2019, part 1.
    Hussar DA
    Nursing; 2019 Feb; 49(2):28-36. PubMed ID: 30676555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
    J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs 2015, part 3.
    Hussar DA
    Nursing; 2015 Oct; 45(10):30-7; quiz 37-8. PubMed ID: 26352370
    [No Abstract]   [Full Text] [Related]  

  • 13. [Deflazacort is an effective and safe alternative to current corticoids].
    Med Clin (Barc); 1991 Mar; 96(8):suppl 1p.. PubMed ID: 2041397
    [No Abstract]   [Full Text] [Related]  

  • 14. Deflazacort: towards selective glucocorticoid receptor modulation?
    Walker BR
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):13-5. PubMed ID: 10651748
    [No Abstract]   [Full Text] [Related]  

  • 15. Does deflazacort therapy offer any advantages over conventional corticosteroids in children with renal disease?
    Clark G
    Pediatr Nephrol; 1997 Jun; 11(3):394. PubMed ID: 9203206
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on the study of deflazacort versus prednisone in the treatment of chronic inflammatory disorders.
    Messina OD; Barreira JC
    Arthritis Rheum; 1992 Jul; 35(7):841-2. PubMed ID: 1622425
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders.
    Gray RE; Doherty SM; Galloway J; Coulton L; de Broe M; Kanis JA
    Arthritis Rheum; 1991 Mar; 34(3):287-95. PubMed ID: 2003854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
    Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
    Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
    Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient osteoporosis of the hip: successful response to deflazacort.
    Carmona-Ortells L; Carvajal-Méndez I; García-Vadillo JA; Alvaro-Gracia JM; González-Alvaro I
    Clin Exp Rheumatol; 1995; 13(5):653-5. PubMed ID: 8575148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.